{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:23Z","timestamp":1790352563100,"version":"4.1.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.leukres.2008.06.002","type":"journal-article","created":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T00:24:55Z","timestamp":1216254295000},"page":"11-18","source":"Crossref","is-referenced-by-count":41,"title":["Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer"],"prefix":"10.1016","volume":"33","author":[{"given":"Hans Carl","family":"Hasselbalch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.06.002_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archinte.1967.00300040030005","article-title":"Agnogenic myeloid metaplasia. Natural history and treatment","volume":"120","author":"Silverstein","year":"1967","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005792-197109000-00001","article-title":"The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome","volume":"50","author":"Ward","year":"1971","journal-title":"Medicine"},{"key":"10.1016\/j.leukres.2008.06.002_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0609.1990.tb00419.x","article-title":"Idiopathic myelofibrosis. A review","volume":"45","author":"Hasselbalch","year":"1990","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.leukres.2008.06.002_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(97)90022-9","article-title":"Idiopathic myelofibrosis: pathogenesis, natural history and management","volume":"11","author":"Reilly","year":"1997","journal-title":"Blood Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.leukres.2008.06.002_bib5","first-page":"3","article-title":"The chronic myeloproliferative disorders","volume":"36","author":"Tefferi","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib6","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1999.17.9.2954","article-title":"Myelofibrosis with myeloid metaplasia: a diagnostic definition and prognostic classification for clinical studies and treatment guidelines","volume":"17","author":"Barosi","year":"1999","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.leukres.2008.06.002_bib7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib8","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"issue":"April (2 Suppl. 3)","key":"10.1016\/j.leukres.2008.06.002_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2004.02.011","article-title":"The chronic myeloproliferative disorders: clonality and clinical heterogeneity","volume":"41","author":"Spivak","year":"2004","journal-title":"Semin Hematol"},{"issue":"April (2 Suppl. 3)","key":"10.1016\/j.leukres.2008.06.002_bib10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminhematol.2004.02.007","article-title":"Treatment paradigms in the management of chronic myeloproliferative disorders","volume":"41","author":"Fruchtman","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib11","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"Mechanisms of disease. The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.leukres.2008.06.002_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.leukres.2008.06.002_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.leukres.2008.06.002_bib14","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.1979.tb03739.x","article-title":"Transitional myeloproliferative disorder","volume":"43","author":"Pettit","year":"1979","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1984.tb01283.x","article-title":"The \u201cspent\u201d phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis","volume":"56","author":"Najean","year":"1984","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.leukres.2008.06.002_bib17","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","article-title":"Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis and leukaemia","volume":"165","author":"Chim","year":"2005","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.leukres.2008.06.002_bib18","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients","volume":"21","author":"Alvarez-Larran","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.002_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2008.06.002_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1600-0609.2008.01038.x","article-title":"20+ years without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis","volume":"80","author":"Tefferi","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s002770000278","article-title":"Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis","volume":"80","author":"Thiele","year":"2001","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.leukres.2008.06.002_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/10428190500331329","article-title":"A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders","volume":"47","author":"Thiele","year":"2006","journal-title":"Leukemia Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2008.06.002_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: inter-observer reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib24","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib25","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.1997.782714.x","article-title":"Identification of \u201cshort-lived\u201d and \u201clong-lived\u201d patients at presentation of idiopathic myelofibrosis","volume":"97","author":"Cervantes","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib27","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/cncr.22630","article-title":"Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis base on 334 patients from a single institution","volume":"109","author":"Tefferi","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2008.06.002_bib28","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2007-09-112953","article-title":"Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis","volume":"111","author":"Vener","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.06.002_bib30","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2008.06.002_bib31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of \u2013function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.leukres.2008.06.002_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.leukres.2008.06.002_bib34","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2008.06.002_bib35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2008.06.002_bib36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib37","doi-asserted-by":"crossref","unstructured":"Li S, Kralovics R, De Libero G, Theocharides A, Gisslinger H, Skoda RC. Clonal heterogeneity in polycythemia vera patients with JAK2 exon 12 and JAK2-V617F mutations. Blood 2008; Jan 14 [Epub ahead of print].","DOI":"10.1182\/blood-2007-09-111971"},{"issue":"10","key":"10.1016\/j.leukres.2008.06.002_bib38","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib39","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.002_bib40","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2008.06.002_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.leukres.2008.06.002_bib42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.leukres.2008.06.002_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.002_bib44","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2(V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib45","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2006-942759","article-title":"The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia","volume":"32","author":"Belluci","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"10.1016\/j.leukres.2008.06.002_bib47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"The V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.leukres.2008.06.002_bib48","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.002_bib49","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.exphem.2007.08.011","article-title":"The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia","volume":"35","author":"Hsiao","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib50","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2008.06.002_bib51","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/sj.leu.2404724","article-title":"Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera","volume":"21","author":"Tefferi","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2008.06.002_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis\u2014impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib53","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib54","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.002_bib55","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.leukres.2008.06.002_bib56","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2008.06.002_bib57","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2 (V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2008.06.002_bib58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2141.2006.06288.x","article-title":"JAK2 V617F mutation in leukemic transformation of Philadelphia-negative chronic myeloproliferative disorders","volume":"135","author":"Rossi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib60","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib61","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","article-title":"Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha","volume":"107","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib62","first-page":"1281","article-title":"Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia","volume":"91","author":"Samuelsson","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib63","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2008.06.002_bib64","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/10245330701384005","article-title":"Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea","volume":"12","author":"Tutaeva","year":"2007","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.leukres.2008.06.002_bib65","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-006-0214-1","article-title":"Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F","volume":"86","author":"Steimle","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib66","doi-asserted-by":"crossref","unstructured":"Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008; May 15 [Epub ahead of print].","DOI":"10.1007\/s00277-008-0498-4"},{"key":"10.1016\/j.leukres.2008.06.002_bib67","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00199157","article-title":"Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders","volume":"25","author":"Ludwig","year":"1987","journal-title":"Cancer Immunol Immunotherapy"},{"key":"10.1016\/j.leukres.2008.06.002_bib68","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0140-6736(89)92142-9","article-title":"Long term interferon therapy for thrombocytosis in myeloproliferative diseases","volume":"1","author":"Gisslinger","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.leukres.2008.06.002_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2141.1990.tb02531.x","article-title":"Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis","volume":"74","author":"Chott","year":"1990","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.06.002_bib70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","article-title":"Interferon-alpha in the treatment of essential thrombocythemia","volume":"22","author":"Lengfelder","year":"1996","journal-title":"Leukemia Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2008.06.002_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10428199609074372","article-title":"Interferon treatment in polycythaemia vera","volume":"22","author":"Reilly","year":"1996","journal-title":"Leukemia Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2008.06.002_bib72","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2008.06.002_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.1999.tb01110.x","article-title":"The effects of interferon alpha on myeloproliferation and vascular complications in polycythemia vera","volume":"62","author":"Heis","year":"1999","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.leukres.2008.06.002_bib74","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s002770050554","article-title":"The role of interferon-alpha in the treatment of idiopathic myelofibrosis","volume":"78","author":"Bachleitner-Hofmann","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon-alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib76","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","article-title":"Essential thrombocythaemia. Challenges and evidence-based management","volume":"130","author":"Harrison","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib77","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.leukres.2007.12.001","article-title":"The hemangioblast does exist","author":"Ribatti","year":"2008","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2008.06.002_bib78","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2006-05-021527","article-title":"Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis","volume":"108","author":"Boissinot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib79","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.leukres.2008.06.002_bib80","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","article-title":"Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis","volume":"44","author":"Primignani","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.leukres.2008.06.002_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.10358","article-title":"The V617F mutation of JAK2 is very uncommon in patients with thrombosis","volume":"92","author":"Remacha","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib82","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/sj.leu.2404710","article-title":"JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.002_bib83","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A Report on 241 cases. Blood 2008; February 4 [Epub ahead of print].","DOI":"10.1182\/blood-2007-11-125328"},{"key":"10.1016\/j.leukres.2008.06.002_bib84","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","article-title":"Increased platelet activation and abnormal glycoprotein content and redistribution in myeloproliferative disorders","volume":"110","author":"Jensen","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib85","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1034\/j.1600-0609.2001.00359.x","article-title":"Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count","volume":"66","author":"Jensen","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib87","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.leukres.2008.06.002_bib88","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2006-10-048298","article-title":"Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu\/BCAM","volume":"110","author":"Wautier","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib89","first-page":"132","article-title":"Therapeutic recommendations in polythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.06.002_bib91","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.06.002_bib92","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1365-2141.2002.03474.x","article-title":"Current trends in essential thrombocythaemia","volume":"117","author":"Harrison","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.06.002_bib93","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib94","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.06.002_bib95","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","article-title":"Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia","volume":"107","author":"Schafer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib96","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.beha.2005.07.007","article-title":"Evidence-based management of polycythemia vera","volume":"19","author":"Barbui","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.leukres.2008.06.002_bib97","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-2006-942764","article-title":"Update on diagnosis and management of essential thrombocythemia","volume":"32","author":"Gisslinger","year":"2006","journal-title":"Semin Thromb Hemostat"},{"key":"10.1016\/j.leukres.2008.06.002_bib98","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-2007-976166","article-title":"Therapy of polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk","volume":"33","author":"Barbui","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.leukres.2008.06.002_bib99","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2006-12-038968","article-title":"How I treat polycythemia vera","volume":"109","author":"Finazzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Finazzi","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib102","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/oxfordjournals.aje.a117095","article-title":"White blood cell count and stroke incidence and death:the NHANES I epidemiological follow-up study","volume":"139","author":"Gillum","year":"1994","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.leukres.2008.06.002_bib103","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.ATV.0000156877.94472.a5","article-title":"Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?","volume":"25","author":"Coller","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.leukres.2008.06.002_bib104","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib105","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leucocytosis and other risk factors for thrombosis in esssential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.06.002_bib106","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.leukres.2008.06.002_bib107","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.leukres.2008.06.002_bib108","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study","volume":"90","author":"Langer","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.06.002_bib109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-2006-942761","article-title":"Pegylated interferon therapy or patients with Philadelphia chromosome-negative myeloproliferative disorders","volume":"32","author":"Quintas-Cardama","year":"2006","journal-title":"Sem Thromb Hemostas"},{"key":"10.1016\/j.leukres.2008.06.002_bib110","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.002_bib111","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.002_bib112","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","article-title":"PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a phase 2 study","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.06.002_bib113","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J Leucocyte Biol"},{"key":"10.1016\/j.leukres.2008.06.002_bib114","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.STR.0000204354.06965.44","article-title":"Metabolic syndrome and the risk of stroke in middle aged men","volume":"37","author":"Kurl","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.leukres.2008.06.002_bib115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2796.2007.01831.x","article-title":"Hyperglycaemia and cardiovascular disease","volume":"262","author":"Bartnik","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib116","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2008.06.002_bib117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1160\/TH04-07-0453","article-title":"Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin","volume":"93","author":"Evangelista","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.leukres.2008.06.002_bib118","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2796.2007.01828.x","article-title":"How can we prevent cardiovascular disease in diabetes","volume":"262","author":"Wiiklund","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib119","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.06.002_bib120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.leukres.2005.12.018","article-title":"Statins in polycythaemia vera and allied disorders. A cytoreductive and antithrombotic potential?","volume":"10","author":"Hasselbalch","year":"2006","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2008.06.002_bib121","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.06.002_bib122","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The role of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.leukres.2008.06.002_bib123","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.leukres.2008.06.002_bib124","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metplasia","volume":"98","author":"Barosi","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2008.06.002_bib125","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1182\/blood-2004-08-3238","article-title":"Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Xu","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2008.06.002_bib126","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/138945007779940133","article-title":"The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders","volume":"8","author":"Hasselbalch","year":"2007","journal-title":"Curr Drug Targets"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T06:01:29Z","timestamp":1684476089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608002786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0145212608002786"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.06.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}